1403.1: A Phase 1, dosing study of brigimadlin (MDM2-p53 antagonist) in patients with advanced solid tumors
NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381. Accessed September 2023.
NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381. Accessed September 2023.